What a warning letter is
A warning letter tells a company that FDA considers certain products, practices, or records to be in significant violation of the law, and asks for a response. FDA’s Regulatory Procedures Manual calls warning letters “informal and advisory.” As Duane Morris explains, a warning letter does not necessarily represent FDA’s final position and is not final agency action, which is why companies generally cannot take it to court.
Timing is uneven. The manual sets internal review windows of 15 working days at each step, but letters often arrive three to four months after an inspection, and sometimes a year or more later.
FDA posts letters on fda.gov with a disclaimer that matters for AI use: the matters described may have changed since the letter was issued, through later interaction between FDA and the recipient. A letter is a snapshot of FDA’s view on a date, not a current description of the company.
Where to find it
- FDA Warning Letters page: searchable by company, issuing office, subject, and date, with letters published in redacted form.
- Close-out letters, where issued, appear alongside the original letter.
- Inspection observations (see the Form 483 article) give the earlier, observation-stage view.
Reuse terms
FDA-authored content on fda.gov is in the public domain unless otherwise noted, so warning letter text is generally reusable. Our conditions are about accuracy, not copyright:
- State the date and stage. A letter reflects FDA’s view when issued, not the outcome.
- Check for later developments, such as a close-out letter or the company’s response.
- Avoid defamation risk in published outputs: summarize what FDA alleged, not what the company “did.”
Using warning letters in AI and RAG
- Download from fda.gov and record the issue date, posting date, issuing office, and letter reference number.
- Add a status field: open, close-out issued, or unknown. Update it on a schedule.
- Tag the CFR citations in each letter so trend questions can be answered by regulation section.
- Store FDA’s disclaimer with each document so answers can repeat it.
- Phrase outputs carefully: “FDA alleged in a 2025 warning letter that…” rather than “Company X violates…”
- Keep warning letters separate from your own correspondence with FDA, which is confidential.
Common mistakes
- Describing a warning letter as a final ruling or a penalty.
- Showing an old letter in a supplier assessment without checking for a close-out.
- Counting letters as “violations” in dashboards without explaining what they are.
- Losing the issue date during chunking, so the model cannot tell old from new.
Checklist
- Letters downloaded from fda.gov with issue date and office recorded
- Status field (open, closed, unknown) maintained
- FDA disclaimer stored with each record
- CFR citations tagged
- Output wording reviewed for “alleged” framing
- Supplier-related use reviewed by legal
How AskDona helps
AskDona lets you ask, for example, which 21 CFR 211 sections are most often cited in recent letters to sterile manufacturers, then compare those themes with your own SOPs. Each answer cites the letters and dates it used.
Run a sample warning-letter trend check
AskDona shows the evidence; your compliance team decides.
Editor’s note. This article is general information, not legal advice. The “conditional use” rating comes from our source list and is a first-pass judgment, not a legal opinion.
FAQ
Is an FDA warning letter final agency action? Generally no. FDA’s procedures describe it as informal and advisory, and it does not necessarily represent FDA’s final position.
Can I reuse warning letter text in my AI tool? Generally yes, since FDA-authored content is public domain unless noted. Keep dates, status, and FDA’s disclaimer with each letter.
How long after an inspection does a warning letter arrive? It varies. Months is common, and a year or more is possible.
Does a warning letter mean the problem still exists? Not necessarily. FDA warns that matters may have changed since issue, so check for close-out letters and later information.
References
All pages opened and checked by October 26, 2026.
| Source | What it supports |
|---|---|
| FDA Warning Letters | Where letters are posted; disclaimer that matters may have changed |
| Duane Morris: FDA Warning Letters Explained (Nov 21, 2023) | “Informal and advisory,” not final agency action, timing |
| FDA Website Policies | Public domain status of fda.gov content, unless otherwise noted |